Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
May 15 ACAD Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
May 14 ALZN Alzamend Neuro Announces Initial Closing of Private Placement
May 14 PRTA News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
May 12 ACAD Cantor picks 14 undervalued biotech stocks worth a second look
May 12 EHAB Insider Spends US$82k Buying More Shares In Enhabit
May 12 PRTA Analysts Have Lowered Expectations For Prothena Corporation plc (NASDAQ:PRTA) After Its Latest Results
May 11 EHAB Enhabit, Inc. (EHAB) Q1 2023 Earnings Call Transcript
May 11 ACAD Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10 AMLX Amylyx Pharmaceuticals Reports Q1 2024 Financial Results
May 10 EHAB Enhabit Inc (EHAB) Reports Mixed Q1 2024 Results: Challenges and Strategic Adjustments Highlighted
May 10 AMLX Breaking Down Amylyx Pharma: 9 Analysts Share Their Views
May 10 ACAD ACADIA Pharmaceuticals Q1 2024 Earnings: Solid Growth with New Product Launches
May 10 AMLX Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript
May 10 ACAD ACADIA Pharmaceuticals First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 9 ACAD Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 9 ACAD ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2024 Earnings Call Transcript
May 9 PRTA Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
May 9 AMLX Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2024 Earnings Call Transcript
May 9 ALZN Alzamend Neuro enters private placement of up to $25M
May 9 ALZN EXCLUSIVE: Alzamend Neuro To Raise Up To $25M Via Private Placement Of Preferred Shares
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags